Open AccessElevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders
Author(s) -
Shu Yaqing,
Li Haiyan,
Zhang Lei,
Wang Yuge,
Long Youming,
Li Rui,
Qiu Wei,
Lu Zhengqi,
Hu Xueqiang,
Peng Fuhua
Publication year - 2017
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.584
Subject(s) - cerebrospinal fluid , medicine , neuromyelitis optica , gastroenterology , uric acid , multiple sclerosis , blood–brain barrier , pathology , immunology , central nervous system
Previous studies have shown that serum uric acid ( UA ) modulates outcomes of neurological diseases, although little is known about cerebrospinal fluid ( CSF ) UA levels in neuromyelitis optica spectrum disorders ( NMOSD s). Methods Cerebrospinal fluid and serum UA levels were measured in samples from 68 patients, including NMOSD s during relapse ( n = 38) and controls with noninflammatory and non‐neurodegenerative diseases ( CTL s, n = 30). Correlation analysis was performed between CSF UA and clinical characteristics, serum UA , and blood–brain barrier integrity in NMOSD s. Results Cerebrospinal fluid UA levels in NMOSD s were significantly higher than in CTL s ( p = .002), while serum UA differences between NMOSD s and CTL s were not statistically significant. In NMOSD s, CSF UA levels were significantly higher in patients with an impaired blood–brain barrier than in patients with an intact one ( p < .001), and significantly higher in longer disease duration than in shorter disease duration patients ( p = .002). CSF UA levels were also significantly higher in active patients upon MRI than in inactive patients ( p < .001), and significantly higher in patients with brain lesions than without brain lesions ( p = .024). CSF UA was significantly associated with the serum UA levels ( r = .454, p = .002), disease duration ( r = .383, p = .018), and blood–brain barrier index ( r = .805, p < .001), but did not correlate with age, gender, annualized relapse rate, duration, or severity of NMOSD . Multiple regression analysis demonstrated that CSF UA was independent of the blood–brain barrier index (β = .765, p < .001) and serum UA levels (β = .01, p = .019) in NMOSD s. Conclusions Cerebrospinal fluid UA levels were elevated in NMOSD patients during relapse, and were likely modified by serum UA levels and blood–brain barrier integrity.